Shares of Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) traded up 2% during mid-day trading on Wednesday . The stock traded as high as $1.53 and last traded at $1.53. 292,991 shares traded hands during mid-day trading, a decline of 21% from the average session volume of 368,852 shares. The stock had previously closed at $1.50.
Wall Street Analyst Weigh In
Separately, Canaccord Genuity Group assumed coverage on Fractyl Health in a report on Tuesday, April 15th. They set a "buy" rating and a $12.00 price objective on the stock.
View Our Latest Report on GUTS
Fractyl Health Stock Performance
The company has a market cap of $74.45 million, a P/E ratio of -0.82 and a beta of 1.58. The company has a current ratio of 2.50, a quick ratio of 2.50 and a debt-to-equity ratio of 4.61. The business has a 50 day moving average price of $1.82 and a 200-day moving average price of $1.61.
Fractyl Health (NASDAQ:GUTS - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.49) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.49). Fractyl Health had a negative return on equity of 228.66% and a negative net margin of 73,864.52%. Analysts forecast that Fractyl Health, Inc. will post -1.61 earnings per share for the current fiscal year.
Institutional Trading of Fractyl Health
Several large investors have recently modified their holdings of GUTS. Raymond James Financial Inc. bought a new position in Fractyl Health in the fourth quarter valued at about $34,000. Intech Investment Management LLC bought a new position in Fractyl Health in the fourth quarter valued at about $34,000. Chicago Partners Investment Group LLC bought a new position in Fractyl Health in the first quarter valued at about $37,000. Jane Street Group LLC raised its position in Fractyl Health by 125.8% in the fourth quarter. Jane Street Group LLC now owns 22,700 shares of the company's stock valued at $47,000 after purchasing an additional 12,648 shares during the last quarter. Finally, HighTower Advisors LLC raised its position in Fractyl Health by 57.9% in the first quarter. HighTower Advisors LLC now owns 40,921 shares of the company's stock valued at $49,000 after purchasing an additional 15,000 shares during the last quarter.
Fractyl Health Company Profile
(
Get Free Report)
Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Featured Stories
Before you consider Fractyl Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fractyl Health wasn't on the list.
While Fractyl Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
